DealsPE-backed Resonetics to acquire the SASE medical nitinol businessThe deal is valued at $900 million.ByIris Dorbian9 January 2023•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs